Status | Study |
Not yet recruiting |
Study Name: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors Condition: Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma Date: 2016-07-18 Interventions: Radiation: Carbon ions therapy |
Recruiting |
Study Name: Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Condition: Adenoid Cystic Carcinoma Date: 2016-05-19 Interventions: Drug: Lenvatinib |
Recruiting |
Study Name: A Study of Apatinib in Metastatic Adenoid Cystic Carcinoma of the Head and Neck Condition: Adenoid Cystic Carcinoma Date: 2016-05-12 Interventions: Drug: Apatinib Mesylate Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecu |
Completed |
Study Name: Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) Condition: Adenoid Cystic Carcinoma Date: 2016-01-22 Interventions: Drug: Brontictuzumab 1.5 mg/Kg intravenously every three weeks. |
Active, not recruiting |
Study Name: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Condition: Mucositis Oral Complications Recurrent Date: 2014-04-23 Interventions: Drug: acetylcysteine Oral rins |
Active, not recruiting |
Study Name: Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Condition: Adenoid Cystic Carcinoma Date: 2014-03-24 Interventions: Drug: Regorafenib All eligible patients will receive a starting regorafenib dose of 120 mg daily taken o |
Recruiting |
Study Name: 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Condition: Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gli Date: 2013-03-05 Interventions: Drug: fludeoxyglucose F 18 Und |
Completed |
Study Name: A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Condition: Recurrent Adenoid Cystic Carcinoma of the Salivary Glands Metas Date: 2012-08-23 Interventions: Drug: Dovitinib Treatment continued until Disease Progression, Toxicity, or patient withdrawal |
Active, not recruiting |
Study Name: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Condition: Recurrent Oral Cavity Adenoid Cystic Carcinoma Recurrent Saliva Date: 2012-05-22 Interventions: Drug: Akt Inhibitor MK2206 Giv |
Completed |
Study Name: Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Condition: Adenoid Cystic Carcinoma Date: 2012-03-16 Interventions: Drug: AG-013736 (AXITINIB) All eligible patients will receive a starting axitinib dose of 5 mg twice dai |